The biweekly GEM plus CBDCA dose and schedule showed satisfactory efficacy with mild toxicities in elderly patients with advanced NSCLC.
1 and 15 every 4 weeks). The primary endpoint was the objective response rate (ORR), and the secondary endpoints were progression-free survival (PFS), overall survival (OS), and safety. Results. Forty-eight patients were enrolled. Median age was 76 years (range, 70-83); 35 patients were men (73%), and 27 patients had adenocarcinoma (56%). The ORR was 29.2% (95% confidence interval [CI], 17.0-44.1). The median PFS, median OS, and 1-year survival was 5.9 months (95% CI, 4.1-6.6), 13.3 months (95% CI, 8.3-23.5), and 58%, respectively. Grade ≥3 hematological toxicities included neutropenia (29.2%), thrombocytopenia (4.2%), and anemia (20.8%). The incidence of grade ≥3 nonhematological toxicities was <5%.
Conclusion. This GEM-CBDCA combination administered biweekly showed satisfactory efficacy with mild toxicities in elderly patients with advanced NSCLC. The Oncologist 2019;24:1-8
DISCUSSION
The incidence of lung cancer increases with age [1] . More than 45% of patients with lung cancer are diagnosed at ≥75 years [2] , and this proportion is likely to increase. In patients with advanced NSCLC, chemotherapy improves survival, diseaserelated symptoms, and quality of life, and combination chemotherapy involving newer agents is now considered the standard first-line treatment [3] . However, combination chemotherapy causes increased hematologic and neuropsychiatric toxicity in older patients [4, 5] , and >90% of elderly patients experience grade ≥3 toxicity when treated with platinum-based combination chemotherapy [6] . Therefore, single-agent chemotherapy is considered the standard treatment for elderly patients with advanced NSCLC [7-9]. An effective, less toxic therapy might be beneficial for a greater proportion of older patients.
The phase III JCOG0803/WJOG4307L trial, which included elderly patients, compared weekly CDDP-docetaxel (DTX) and DTX alone. An interim analysis showed that combination therapy did not outperform monotherapy (OS 13.3 months vs. 14.8 months, hazard ratio [HR], 1.18; 95% CI, 0.83-1.69) [10] . The IFCT0501 trial, which also included elderly patients, compared CBDCA-weekly paclitaxel (PTX) with GEM or vinorelbine (VNR) and found a significantly prolonged PFS (6.0 months vs. 2.8 months; HR, 0. 51; 95% CI, 0.42-0.62, p < .0001) and OS (10.3 months vs. 6.2 months; HR, 0.64; 95% CI: 0.52-0.78, p < .0001) with combination therapy. However, this outcome is not greatly superior to that observed with monotherapy, and the rate of treatment-related death in the combination group was 4.4% [11] .
The combination of GEM and CBDCA is already widely administered as standard therapy for NSCLC in Europe and America, and some usefulness in the elderly is also reported [12] . In Japan, the phase II randomized WJTOG-0104 trial examined GEM-CBDCA (3 weeks) and GEM-VNR in younger patients (<75 years) with advanced NSCLC. GEM-CBDCA had a good effect, with an ORR of 20.3% (GEM-VNR, 21.0 %), a median survival time (MST) of 14.2 months (GEM-VNR, 12.6 months), and a 2-year survival rate of 38.3% (GEM-VNR, 22.4%) [13] . However, a high incidence of thrombocytopenia was observed in the GEM-CBDCA group, and, therefore, the optimal dosage and administration schedules must still be defined. Our group has previously conducted a clinical trial of biweekly CBDCA-PTX, which resulted in a more favorable hematologic toxicity profile, and we considered that this biweekly administration schedule may be useful for the GEM-CBDCA combination in view of the differences in thrombocytopenia incidence between GEM and CBDCA, and an improvement in the acceptability of this administration schedule can be expected [14] . Therefore, we conducted a phase II study of biweekly administration of GEM-CBDCA to establish a highly acceptable and useful treatment for elderly patients with NSCLC.
This phase II study was developed with the intent of reducing toxicity without lowering efficacy compared with the standard 3-week regimen in elderly patients in which chemotherapy is administered on days 1 and 8 of a 21 day cycle. The ORR was 29.2% (3- week regimen in WJTOG-0104 trial, 21.0 %). The median PFS was 178 days (95% CI, 122-198), and the median OS was 398 days (95% CI, 248-704; 3-week regimen in WJTOG-0104 trial, 14.2 months). The toxicity profile was generally mild and tolerable. On the basis of these results, the biweekly GEM-CBDCA regimen-administered on days 1 and 15 of a 28 day cycle-could be considered an alternative to the 3-week regimen for NSCLC.
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The sample size was calculated at an α error of 0.05 and β error of 0.2. The expected response rate and threshold response rate are determined to be 25% and 10%, respectively. The estimated minimum sample size was 43, and considering the potential patient dropout, we planned to enroll 48 patients.
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In elderly patients, assessment of the degree of progression of lung cancer and predictors of response to treatment (e.g., driver oncogenes, such as epidermal growth factor receptor [EGFR] mutation and ALK fusion gene, and tumor programmed death-ligand 1 expression), as well as assessment and prediction of an individual's ability to tolerate treatment, are critical. In drug development trials, young people with good performance status tend to be clustered as the major population, and immediate application of the results to the elderly may not be appropriate. For this reason, clinical trials in the elderly have been conducted in Japan and overseas [8, 10, [15] [16] [17] . These trials have had several important findings. First, compared with best supportive care, single-agent cytocidal anticancer therapy prolongs survival. Second, as monotherapy, vinorelbine, and gemcitabine (GEM) are the first-line drugs in Europe, and docetaxel (DTX) is the first-line drug in Japan. All of these treatments are used in both Europe and Japan, but the recommended dosage is lower in Japan than in Europe and in the U.S. In Japan, there is much evidence of DTX, which is often the first choice of treatment. In contrast, the use of vinorelbine tends to be less frequent in the U.S. Third, clinical trials comparing split-dose cisplatin plus DTX versus DTX monotherapy in Japan showed that the primary endpoint, survival, was not prolonged with combination therapy. Currently, the Japanese Lung Cancer Practice Guidelines recommend single-agent treatment with DTX and other thirdgeneration anticancer drugs for patients aged 75 years or older with stage IV non-small cell lung cancer (NSCLC) and a negative or unknown driver oncogene or EGFR mutation, ALK translocation, or ROS1 translocation. In the present study, the response rate was 29.2% (95% confidence interval [CI], 17.0-44.1), and the primary endpoint was met. This was more favorable than the response rates of single-agent DTX or single-agent tegafur-gimeracil-oteracil (S-1), with confirmed noninferiority to single-agent DTX [17] . The median progression-free survival was 178 days (95% CI, 122-198), the median overall survival was 398 days (95% CI, 248-704), and the 1-year survival was 57.5%. These results are comparable to the results of previous clinical studies in the elderly. Toxicity was generally mild, with grade 3 or greater neutropenia occurring in 29.2% of patients and thrombocytopenia in 4.2%. We conclude that this treatment regimen is appropriate for a validation group in phase III trials.
Pemetrexed (PEM), which is incorporated into standard therapy in nonelderly patients with non-squamous cell carcinoma, is also a promising drug for the treatment of the elderly, but there is insufficient evidence for this. Recently, a phase III trial in Japan comparing DTX monotherapy with CBDCA + PEM in non-squamous cell carcinoma patients aged 75 years or older found that the median overall survival was 15.5 months (95% CI, 13.6-18.4) in the DTX monotherapy group and 18.7 months (95% CI, 16.0-21.9) in the CBDCA-PEM therapy group, with a stratified hazard ratio of 0.850 (95% CI, 0.684-1.056). The upper limit of the 95% CI of the p value, 1.056, was below 1.154, thus proving the noninferiority of CBDCA-PEM therapy. The progression-free survival favored CBDCA-PEM therapy, with a hazard ratio of 0.739 (95% CI, 0.609-0.89). Response rates were also higher in the CBDCA-PEM arm; DTX monotherapy had a response rate of 28.2% and CBDCA-PEM therapy a response rate of 36.8% (p = .0740). In Japan, we recently obtained marketing approval for the use of necitumumab, an antimonoclonal antibody against EGFR, for unresectable advanced and recurrent squamous cell NSCLC. Since necitumumab is administered concomitantly with GEM plus platinum, the regimen in this study may also be applicable to treatment with necitumumab.
The results of this study met the criteria for the primary endpoint. Combination chemotherapy with CBDCA and GEM was found to be effective and well-tolerated in elderly patients with NSCLC. These results warrant further evaluation of this combination in phase III trials.
